Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Copenhagen, 2015-11-06 08:13 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the first public presentation of the...
-
Copenhagen, 2015-11-05 08:25 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative...
-
Copenhagen, 2015-11-03 08:45 CET (GLOBE NEWSWIRE) -- Bestyrelsen for Exiqon A/S har den 2. november 2015 besluttet at udstede 1.200.000 stk. warrants til direktionen i Exiqon A/S. Samtlige warrants...
-
Copenhagen, 2015-11-03 08:45 CET (GLOBE NEWSWIRE) -- The supervisory board of Exiqon A/S has on 2 November 2015 resolved to issue 1,200,000 warrants to the executive board of Exiqon A/S. All...
-
Copenhagen, 2015-10-30 12:16 CET (GLOBE NEWSWIRE) -- Exiqon A/S, der er noteret på NASDAQ Copenhagen (“EXQ”), meddeler, at Danske Bank koncernen (CVR-nr. 61126228) med adresse på Holmens Kanal 2-12,...
-
Copenhagen, 2015-10-30 12:16 CET (GLOBE NEWSWIRE) -- Exiqon A/S, listed on NASDAQ Copenhagen (“EXQ”), has been informed that Danske Bank Group (CVR-nr. 61126228) with an address at Holmens Kanal...
-
Copenhagen, 2015-10-26 13:52 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the third quarter and first nine months of...
-
Copenhagen, 2015-10-08 15:13 CEST (GLOBE NEWSWIRE) -- Exiqon A/S, listed on NASDAQ Copenhagen (“EXQ”), has been informed by Teknoinvest VIII KS with its registered office at Smalgangen 3, 0188 Oslo,...
-
Copenhagen, 2015-10-08 15:13 CEST (GLOBE NEWSWIRE) -- Exiqon A/S, der er noteret på NASDAQ Copenhagen (“EXQ”), meddeler, at Teknoinvest VIII KS med adresse på Smalgangen 3, 0188 Oslo, Norge...
-
Copenhagen, 2015-09-02 14:10 CEST (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced that the company has exclusively licensed two sets of validated prostate cancer biomarkers...